Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
KRRO Korro Bio Inc.
- Stocks
- Healthcare
- NASDAQ: KRRO
Price (delayed)
$15.56
Market cap
$146.12M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$9.44
Enterprise value
$127.16M
frequency therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. through the controlled activation of progenitor cells, frequency enables disease modification without the
Highlights
Korro Bio's revenue has surged by 112% QoQ
Korro Bio's gross profit has soared by 112% from the previous quarter
KRRO's quick ratio is down by 30% year-on-year but it is up by 6% since the previous quarter
KRRO's EPS has shrunk by 157% YoY
Korro Bio's debt has increased by 26% YoY
Key stats
What are the main financial stats of KRRO
Market
Valuations
Earnings
Shares outstanding
9.39M
Market cap
$146.12M
Enterprise value
$127.16M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.05
Price to sales (P/S)
30.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
26.38
Revenue
$4.82M
Gross profit
$4.82M
Operating income
-$95.48M
Net income
-$87.41M
EBIT
-$87.29M
EBITDA
-$80.95M
Free cash flow
-$75.05M
Per share
Balance sheet
Liquidity
EPS
-$9.44
EPS diluted
-$9.44
Free cash flow per share
-$8
Book value per share
$14.8
Revenue per share
$0.51
TBVPS
$21.55
Total assets
$202.21M
Total liabilities
$63.25M
Debt
$45.19M
Equity
$138.96M
Working capital
$108.35M
Debt to equity
0.33
Current ratio
9.41
Quick ratio
9.07
Net debt/EBITDA
0.23
Margins
Efficiency
Dividend
EBITDA margin
-1,679.2%
Gross margin
100%
Net margin
-1,813.1%
Operating margin
-1,980.4%
Return on assets
-37.9%
Return on equity
-51.6%
Return on invested capital
-45.9%
Return on capital employed
-46.1%
Return on sales
-1,810.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KRRO stock price
How has the Korro Bio stock price performed over time
Intraday
1.04%
1 week
-25.67%
1 month
14.75%
1 year
-71.65%
YTD
-59.13%
QTD
-10.63%
Financial performance
How have Korro Bio's revenue and profit performed over time
Revenue
$4.82M
Gross profit
$4.82M
Operating income
-$95.48M
Net income
-$87.41M
Gross margin
100%
Net margin
-1,813.1%
Korro Bio's revenue has surged by 112% QoQ
Korro Bio's gross profit has soared by 112% from the previous quarter
KRRO's operating margin has soared by 51% QoQ
Korro Bio's net margin has soared by 51% from the previous quarter
Price vs fundamentals
How does KRRO's price correlate with its fundamentals
Growth
What is Korro Bio's growth rate over time
Valuation
What is Korro Bio stock price valuation
P/E
N/A
P/B
1.05
P/S
30.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
26.38
KRRO's EPS has shrunk by 157% YoY
The stock's price to book (P/B) is 48% less than its 5-year quarterly average of 2.0 and 38% less than its last 4 quarters average of 1.7
Korro Bio's equity has decreased by 13% from the previous quarter and by 8% YoY
Korro Bio's revenue has surged by 112% QoQ
Efficiency
How efficient is Korro Bio business performance
KRRO's ROIC has soared by 72% YoY and by 8% from the previous quarter
KRRO's ROS has soared by 51% QoQ
The return on equity is up by 36% year-on-year but it has declined by 6% since the previous quarter
KRRO's return on assets is up by 36% year-on-year but it is down by 4.1% since the previous quarter
Dividends
What is KRRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KRRO.
Financial health
How did Korro Bio financials performed over time
KRRO's total liabilities is up by 36% YoY but it is down by 3.9% QoQ
KRRO's quick ratio is down by 30% year-on-year but it is up by 6% since the previous quarter
Korro Bio's debt is 67% less than its equity
KRRO's debt to equity is up by 38% year-on-year and by 18% since the previous quarter
Korro Bio's debt has increased by 26% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.